P1.11-20 Identification of a Thirteen-Gene Prognostic Signature for Lung Adenocarcinoma

Abstract

The incidence of lung adenocarcinoma has gradually surpassed that of lung squamous cell carcinoma. It is especially important for the diagnosis and treatment of lung adenocarcinoma. Therefore, we used the GEO and TCGA databases to assess the integration of several gene signatures and clinical stages associated with survival. RNA sequencing was performed on LUAD-affected tissues and paired with non-cancerous tissue samples, and the intersection of differentially expressed genes was obtained using the Gene Expression Omnibus datasets GSE117370 and GSE19188, and a protein-protein interaction network was constructed to obtain the hub genes. Then corresponding overall survival information of LUAD patients from The Cancer Genome Atlas project-LUAD were included in the present study. An analysis of the Kyoto Encyclopedia of Genes and Genomes database and Gene Ontology were carried out to study the signature mechanism. In this study, we identified thirteen candidate genes (SPP1, SMAD6, NUF2, NEK2, MMP1, KRT6A, HMMR, GJB2, FAM83A, DEPDC1, COL11A1, CENPF, CCNB1) closely related to survival in LUAD. A linear prognostic model of the eight genes was constructed and weighted by the regression coefficient (β) from the multivariate Cox regression analysis of The Cancer Genome Atlas-LUAD cohort to divide patients into low- and high-risk groups. The prognostic ability of the signature was validated in LUAD patients at our hospital. Patients assigned to the high-risk group exhibited poor overall survival compared to patients in the low-risk group. Finally, functional enrichment analysis showed that cell division played a vital role in the development of LUAD. Our results highlighted a mRNA signature including thirteen genes, which may serve as a potential prognostic marker of LUAD.